Prolaio

Prolaio

Real-time cardiovascular care analytics platform

Overview

Prolaio provides a cardiovascular-focused health tech platform that helps healthcare providers improve patient outcomes through real-time data analytics and continuous monitoring. It collects data from electronic health records, patient surveys, and wearable sensors to build predictive models that warn care teams about potential health issues before they become critical. Healthcare providers access the platform via a subscription, giving them real-time analytics, alerts, and evidence-based care planning tools to monitor patients and optimize treatments. The company differentiates itself by concentrating on cardiovascular care and enabling continuous learning, patient engagement, and collaboration with pharmaceutical companies and research institutions to support new therapies. The overall goal is to reduce hospital admissions and readmissions while delivering timely, data-driven care that keeps patients healthier.

About Prolaio

Simplify's Rating
Why Prolaio is rated
C-
Rated C on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

51-200

Company Stage

Early VC

Total Funding

$25.5M

Headquarters

Scottsdale, Arizona

Founded

2022

Get referred to Prolaio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Kardigan says Prolaio speeds 2026 readouts across three late-stage cardiovascular programs.
  • The platform collects daily physiologic data from wearable sensors and clinic records.
  • Management says Prolaio improves trial efficiency and raises clinical success probability.

What critics are saying

  • Prolaio lost independence in 2025, so roles depend on Kardigan’s strategy.
  • Kardigan reported no revenue through March 31, 2026, funding everything from investors.
  • If Kardigan’s trials fail, Prolaio becomes a sunk cost with limited standalone demand.

What makes Prolaio unique

  • Prolaio combines FDA-cleared monitoring with cardiovascular analytics and real-world data.
  • Kardigan acquired Prolaio in February 2025, keeping the platform inside a therapeutics company.
  • Its platform supports smaller, faster cardiovascular trials using continuous remote monitoring.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$25.5M

Above

Industry Average

Funded Over

1 Rounds

Early VC funding comparison data is currently unavailable. We're working to provide this information soon!
Early VC Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Stock Options

Company Equity

Retirement Plan: 401(k) plan

Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-6%

2 year growth

-4%
Business Wire
Mar 28th, 2025
Kardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics Platform

Kardigan, a heart health company modernizing cardiovascular (CV) drug development, announced today that it has acquired Prolaio, a clinical intelligence comp...

U.S. Securities and Exchange Commission
Sep 13th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Recently Posted Jobs

Sign up to get curated job recommendations

Prolaio is Hiring for 7 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →